DMF significantly reduced the annualized relapse rate beginning in weeks 0-12 ( BID , P = 0.0159 ; TID , P = 0.0314 ) ; the proportion of patients relapsed beginning at week 10 ( BID , P = 0.0427 ) and week 12 ( TID , P = 0.0451 ) ; and the proportion of patients with 12-week confirmed disability progression beginning at week 62 ( BID , P = 0.0454 ) and week 72 ( TID , P = 0.0399 ) , compared with placebo .